

Why Screen for Cancer?

When it comes to canine cancer, knowledge is your ally. The Nu.Q® Vet Cancer Test isn't just another test; it's a science-backed tool that offers you the time and insight for a proactive care approach, allowing you to make data-driven decisions and guide pet owners with increased confidence.

Bridging Conversations

A test result is more than just a data point; it opens the door for veterinarians to engage in meaningful conversations with pet owners. From treatment options and lifestyle changes to ongoing health monitoring, the Nu.Q® Vet Cancer Test serves as a catalyst for more personalized, compassionate care.

Elevate Your Practice

Integrating this innovative test into wellness plans complements existing preventive measures like vaccines and routine bloodwork. You're not just adopting a new procedure; you're enriching your toolkit for a nuanced, holistic approach to canine wellness.

Where to Find the Nu.Q® Vet Cancer Test





Contact Us



(979) 709-2348



asknu.qvet@volition.com



volition.com/veterinary




NU-Q Cancer Test

"Where compassion meets innovation"

How does the test work?

Nucleosomes are bead like structures comprised of DNA coiling around the histone protein core.





When cancer is present, nucleosomes - originating from the cancer cells - enter the bloodstream.



They can be captured using antibodies tailored specifically to detect nucleosomes.




The Nu.Q® Vet Cancer Test quanitifies these circulating nucleosome levels in the blood.



The test needs just 0.5ml of plasma, obtainable from a 2-5ml blood draw after centrifugation.

The Value of Screening



Clinical Validation: The Research Behind the Results

A peer-reviewed and published case series (September 2022) of 662 dogs.

and peerstudy

134	528
Healthy	With Cancer
7 common cancers were researched ¹	At 97% specificity, the Nu.Q® Vet Cancer Test was able to detect
Lymphoma Mast Cell Tumors Hemangiosarcoma Melanoma Histiocytic Sarcoma Soft Tissue Sarcoma Osteosarcoma Pect access to review winload the full viewed and published can the QR code:	50% of all cancers researched 76% of systemic cancers
	Lymphoma - 77% Hemangiosarcoma - 82%
	Histiocytic sarcoma - 54%